Want to see HK:7630 full AI Analyst Report?
IMPACT Therapeutics, Inc. Class H (7630) AI Stock Analysis
IMPACT Therapeutics, Inc. Class H
(HKEX:7630)
The score is primarily weighed down by weak financial performance—sharp post-2023 revenue contraction, widening losses, negative operating/free cash flow, and balance-sheet stress from persistent negative equity and rising debt. Technicals add further pressure with a clear downtrend (price below key moving averages and negative MACD), while valuation is constrained by a negative P/E and no provided dividend yield.
IMPACT Therapeutics, Inc. Class H (7630) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.35B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.64M
- Price to Earnings (P/E)
- -8.2
- Beta (1Y)
- -0.77
- Revenue Growth
- 394.93%
- EPS Growth
- 15.73%
- Country
- Hong Kong
- Employees
- 88
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
IMPACT Therapeutics, Inc. Class H Business Overview & Revenue Model
Company Description
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IM...
IMPACT Therapeutics, Inc. Class H Financial Statement Overview
Summary
Weak overall financial health: revenue fell sharply after a strong 2023 base and remains low, operating and net losses widened in 2024–2025, and operating/free cash flow turned materially negative. Balance-sheet risk is elevated with negative equity across periods and debt rising from zero (2023) to substantial levels (2024–2025), despite strong gross margins and slightly improved cash burn in 2025 vs 2024.
Income Statement
18Very NegativeBalance Sheet
9Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 17.14M | 5.33M | 4.68M | 33.27M |
| Gross Profit | 14.95M | 4.49M | 3.54M | 32.14M |
| EBITDA | -29.13M | -31.42M | -26.86M | -1.60M |
| Net Income | -36.73M | -41.23M | -35.54M | 519.73K |
Balance Sheet | ||||
| Total Assets | 170.16M | 47.86M | 53.26M | 43.65M |
| Cash, Cash Equivalents and Short-Term Investments | 156.99M | 36.99M | 46.59M | 38.95M |
| Total Debt | 623.31K | 123.32M | 118.21M | 0 |
| Total Liabilities | 55.85M | 184.92M | 155.18M | 57.10M |
| Stockholders Equity | 114.31M | -137.06M | -101.93M | -13.45M |
Cash Flow | ||||
| Free Cash Flow | -14.16M | -13.57M | -12.28M | 3.06M |
| Operating Cash Flow | -14.10M | -13.36M | -12.05M | 3.10M |
| Investing Cash Flow | -11.05M | 15.68M | -57.18M | 17.68M |
| Financing Cash Flow | 115.35M | 1.92M | 62.55M | 5.59M |
IMPACT Therapeutics, Inc. Class H Peers Comparison
Overall Rating
HK:618551Neutral
HK:988742Neutral- HK:763041Neutral
HK:167230Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:6185 | 51Neutral | HKD 13.23B | 632.61 | 0.60% | ― | 36.09% | ― |
| HK:9887 | 42Neutral | HKD 7.16B | -22.08 | -23.34% | ― | ― | 6.66% |
| HK:7630 | 41Neutral | HKD 2.40B | -8.21 | 323.05% | ― | 394.93% | 15.73% |
| HK:1672 | 30Underperform | HKD 5.15B | -7.05 | -28.15% | ― | -59.39% | -130.04% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:7630 | IMPACT Therapeutics, Inc. Class H | 8.51 | -33.35 | -79.68% | |
| HK:1672 | Ascletis Pharma, Inc. | 4.90 | -4.91 | -50.05% | |
| HK:6185 | CanSino Biologics, Inc. Class H | 25.78 | -21.42 | -45.38% | |
| HK:9887 | Nanjing Leads Biolabs Co., Ltd. Class H | 36.00 | -19.40 | -35.02% | |
| HK:2595 | Genfleet Therapeutics (Shanghai), Inc. Class H | 22.50 | -5.00 | -18.18% | |
| HK:1779 | LongBio Pharma (Suzhou) Co., Ltd. Class H | 50.05 | -81.75 | -62.03% |
IMPACT Therapeutics, Inc. Class H Corporate Events
IMPACT Therapeutics Reports Positive PARP Inhibitor Data at 2026 ESMO Congress
IMPACT Therapeutics reported new clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707, showcased in poster presentations at the 2026 ESMO Congress in Madrid. The update underscores the company’s progress in late-stage...
IMPACT Therapeutics Wins EMA Panel Backing for Ovarian Cancer Drug Senaparib
IMPACT Therapeutics said the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for senaparib, branded as Sepalna, as a first-line maintenance treatment...
IMPACT Therapeutics Gains Access to Mainland Investors via Stock Connect
IMPACT Therapeutics, Inc. announced that its H shares have been included in the list of eligible securities under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2026. This listing enables qualified Mainla...
IMPACT Therapeutics CEO Boosts Stake in Hong Kong–Listed Biopharma Group
IMPACT Therapeutics’ chief executive officer and executive director, Dr. Sui Xiong Cai, has increased his stake in the Hong Kong–listed biopharmaceutical company by purchasing 100,000 shares on the open market at an average price of about...
IMPACT Therapeutics Narrows Loss and Strikes Global Senaparib Deal
IMPACT Therapeutics reported a sharp improvement in interim financial performance for the six months ended June 30, 2026, with revenue rising to RMB105.19 million and its period loss narrowing by 29.5% year on year. The company’s adjusted net l...
IMPACT Therapeutics to Join Hang Seng Composite Index, Bolstering Market Reach
IMPACT Therapeutics, Inc., a Hong Kong-listed biotechnology company focused on synthetic lethality-based precision oncology, has developed a broad portfolio of PARP inhibitors and other targeted cancer therapies around an integrated R&D platform....
IMPACT Therapeutics Sets Date to Approve Interim 2026 Results
IMPACT Therapeutics, Inc. has scheduled a board meeting for August 31, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The planned publication of these interim figures will provide investors and other...
IMPACT Therapeutics Advances First PROTAC Candidate IMP2794 for KAT6A-Driven Cancers
IMPACT Therapeutics has nominated IMP2794 as its first preclinical candidate derived from its proprietary targeted protein degradation platform, marking a key milestone in the company’s push into next-generation oncology therapeutics. The KAT6A...
IMPACT Therapeutics Narrows Loss as Senaparib Commercialization Fuels Revenue Surge
IMPACT Therapeutics, Inc. reported a sharp rise in first-half 2026 revenue, projecting between RMB94.7 million and RMB115.7 million, driven by the accelerated commercialization of its cancer drug senaparib after inclusion in China’s National Re...
IMPACT Therapeutics Sets Out Governance Framework for New Audit Committee
IMPACT Therapeutics, Inc. operates in the biopharmaceutical sector and is governed by a board structure aligned with Chinese company law and Hong Kong listing requirements. The company’s H-share listing on the Hong Kong Stock Exchange subjects...
IMPACT Therapeutics Strikes EUR423.5 Million Global Senaparib Deal With Pharmanovia
IMPACT Therapeutics has entered an exclusive licensing partnership with global specialty pharmaceutical firm Pharmanovia, granting it rights to manufacture, develop and commercialise senaparib for maintenance monotherapy in advanced epithelial high-g...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026